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Tyler M. Bauman, BS, Aaron M. Potretzke, MD, Joel M. Vetter, MS,
Sam B. Bhayani, MD, MS, and Robert Sherburne Figenshau, MD
Abstract
Objective: To identify specific comorbidities within the Charlson Comorbidity Index (CCI) that are associated
with increased complication rates after robot-assisted partial nephrectomy (RAPN).
Patients and Methods: After institutional review board approval, a consecutive series of 641 patients undergoing
RAPN were retrospectively identified. Perioperative complications were defined and classified using the Clavien
grading system. Fisher’s exact test or chi-square test was performed to evaluate the association of individual
comorbidities with perioperative complications. Logistic regression was used for multivariable analysis to adjust
for other non-CCI comorbidities and tumor-specific and patient-specific characteristics.
Results: Of the 641 patients undergoing RAPN, complications occurred in 67 patients (10.5%), including 10
(14.9%), 28 (41.8%), 20 (29.9%), 5 (7.5%), and 4 (6.0%) patients with Clavien grade 1, 2, 3a, 3b, and 4
complications, respectively. Cerebrovascular disease [odds ratio 3.01 (95% confidence interval [CI] 1.10, 8.26)
p = 0.03] and chronic obstructive pulmonary disease [COPD; 3.12 (1.24, 7.89) p= 0.02] predicted complications in
multivariable analysis of clinicopathologic characteristics, including all CCI and non-CCI comorbidities. In
additional modeling with only CCI comorbidities, similar results were observed, with cerebrovascular disease
[2.93 (1.04, 7.56) p= 0.04] and COPD [2.69 (1.04, 6.28) p= 0.04] as the only two significant variables. No other
variables reached statistical significance in either model, including nephrometry score or estimated blood loss
( p > 0.50 for both). COPD predicted major complications (Clavien grade 3 or 4) in multivariable analysis [3.19
(1.07, 9.48) p= 0.04].
Conclusions: Cerebrovascular disease and COPD predict perioperative RAPN complications after RAPN.
Identification of patients with these comorbidities preoperatively may afford improved counseling and risk
stratification.
Introduction
Over 61,000 new cases of kidney cancer will be diag-nosed in 2015, leading to over 14,000 cancer-specific
deaths.1 Increased utilization of abdominal imaging has re-
sulted in increased incidental findings of localized renal mas-
ses,2 and current guidelines by the American Urological
Association (AUA) recommend nephron-sparing surgery as
standard of care for patients presenting with small T1 renal
masses consistent with renal-cell carcinoma (RCC).3 Multiple
options with comparable oncologic outcomes exist for man-
agement of localized RCC, including open, laparoscopic, and
robotic partial nephrectomy (PN) and percutaneous ablation.4–6
To better predict complexity of PN and perioperative com-
plications, tumor-specific characteristics are incorporated into
scoring systems such as RENAL nephrometry score (RNS).7
RNS incorporates tumor radius, exophytic/endophytic proper-
ties, proximity to collecting system, anterior/posterior locality,
and location relative to the polar line. RNS has been associated
with perioperative outcomes and complications in previous
studies of small renal tumors and PN.8–10 Despite the objec-
tivity of RNS, this measure alone does not incorporate other
patient-specific characteristics and comorbidities that may
significantly complicate PN and surgical outcomes.
The Charlson Comorbidity Index (CCI) is a weighted
scoring metric designed to account for patients with comorbid
conditions,11 and CCI has been incorporated into many ana-
lyses of kidney cancer surgical and oncologic outcomes.12–15
All-encompassing indices such asCCI provide an advantage of
risk stratification, but may not be the best predictor of out-
comes; comorbidity profiles often differ based on population
and disease state of interest, which can lower the predictive
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power of these indices.16,17 Therefore, the purpose of this study
was to identify specific comorbid conditions within the CCI
that predict perioperative complications after robot-assisted
partial nephrectomy (RAPN) at a high-volume tertiary care
center.
Patients and Methods
After approval was obtained from the Washington Uni-
versity Institutional Review Board, retrospective review of a
consented, deidentified, and prospectively maintained data-
base was performed for patients that underwent RAPN be-
tween 2007 and 2014. All patients demonstrated renal masses
suspicious for RCC upon CT or MRI.
Surgical technique
RAPN operations were performed through a retroperito-
neal or transperitoneal approach using the da Vinci Surgical
System. The techniques for these respective approaches have
been previously described.18,19 The operative approach was
selected based on a composite of the following factors: pa-
tient habitus, history of previous intra-abdominal surgery,
relative anterior–posterior location of the tumor, and surgeon
preference.
Data collection
Staff physicians and data managers prospectively collected
tumor characteristics, perioperative outcomes, and patient
demographics, including the following comorbidities that
contribute to CCI: acquired immunodeficiency, chronic ob-
structive pulmonary disease (COPD), congestive heart fail-
ure, cerebrovascular disease, connective tissue disease,
dementia, diabetes mellitus, hemiplegia, leukemia, lym-
phoma, liver disease, renal disease, myocardial infarction,
peripheral vascular disease (PVD), solid tumor within the last
5 years, and metastases of solid tumor, as outlined previ-
ously.11
Cerebrovascular disease was defined as history of cere-
brovascular accident or transient ischemic attack. Of note, the
kidney tumor for which the patient was undergoing surgery
was not included in the CCI calculation. Other comorbidities
not included in CCI but analyzed in this study include ab-
dominal aortic aneurysm, arrhythmia, asthma, coronary ar-
tery disease, history of deep vein thrombosis, history of renal
stones, hyperlipidemia, hypertension, and spinal cord injury.
Perioperative complications were recorded prospectively
and defined by the Clavien grading system.20 Major compli-
cations were defined as Clavien grade 3 or 4. Hemorrhage was
defined as bleeding sufficient to warrant perioperative blood
transfusion or other therapeutic intervention, or symptomatic
hematoma. Urine leakage was defined either by radiographic
demonstration of extra-pyelocaliceal urine or increased drain
fluid creatinine. Ileus was defined as the necessary placement
of a nasogastric tube due to prolonged return of normal bowel
function.
Statistical analyses
Baseline characteristics between patients with and without
complications were compared using either the Student’s t-test
or chi-square analysis. To evaluate the association of individual
comorbidities with perioperative complications, Fisher’s exact
test was performed. Multivariable analysis was performed
using logistic regression to determine the relationship of indi-
vidual comorbidities with perioperative complications while
adjusting for other comorbidities and tumor-specific and
patient-specific characteristics, including the following: body
mass index (BMI), gender, age, need for pelvicaliceal repair,
off-clamp technique, operative time, estimated blood loss,
RNS, and the absence of any significant comorbidity. All data
analyses were performed using R software v3.1.3, and a two-
tailed p-value <0.05 was defined as significant in all analyses.
Results
A total of 641 patients were identified that underwent
RAPN for renal masses at the Washington University
(Table 1). Complications occurred in 67 patients (10.5%)
after surgery, including 10 (14.9%), 28 (41.8%), 20 (29.9%),
5 (7.5%), and 4 (6.0%) patients with Clavien grade 1, 2, 3a,
3b, and 4 complications, respectively (Table 2). A total of 64
of 67 complications occurred before 30 days after surgery.
We evaluated baseline characteristics between patients with and
without complications using either the Student’s t-test or chi-
square analysis.
Patients with complications had significantly longer oper-
ative times (153.8– 48.1 minutes vs 175.6 – 63.5 minutes,
p = 0.001), higher blood loss (180.7– 235.5mL vs 226.5 –
219.8mL, p= 0.004), and were more likely to need pelvica-
liceal repair (13.0% vs 6.9%; p = 0.01) than patients without
complications. Other demographics were similar between
patients with and without perioperative complications. There
Table 1. Characteristics and Demographics
of Patients Undergoing RAPN
Characteristics
Complications
pNo (n = 574) Yes (n = 67)
BMI, mean (–SD) 30.7 (–6.7) 32.1 (–7.1) 0.17
Age, mean (–SD) 57.4 (–11.8) 59.8 (–11.5) 0.08
Operative time,
mean (–SD)
153.8 (–48.1) 175.6 (–63.5) 0.001
Estimated blood
loss, mean (–SD)
180.7 (–235.5) 226.5 (–219.8) 0.004
Nephrometry,
mean (–SD)
7.5 (–1.9) 8.1 (–1.8) 0.05
Gender, N (%) 0.98
Male 333 (89.5) 39 (10.5)
Female 232 (89.6) 27 (10.4)
Off-clamp, N (%) 0.10
No 428 (88.4) 56 (11.6)




No 243 (93.1) 18 (6.9)
Yes 329 (87.0) 49 (13.0)
CCI, N (%) 0.06
CCI = 0 314 (92.1) 27 (7.9)
CCI = 1 126 (89.4) 15 (10.6)
CCI = 2 72 (85.7) 12 (14.3)
CCI ‡3 62 (82.7) 13 (17.3)
Bold= p < 0.05 and therefore considered significant.
BMI = body mass index; CCI =Charlson Comorbidity Index;
RAPN = robot-assisted partial nephrectomy.
294 BAUMAN ET AL.
was no statistically significant difference in CCI between
patients with and without complications ( p= 0.06).
The association of perioperative complications with indi-
vidual comorbidities was evaluated using Fisher’s exact test.
Within the CCI, we identified the following factors as sig-
nificantly associated with increased rates of complications:
cerebrovascular disease ( p < 0.001), COPD ( p = 0.003), dia-
betes mellitus ( p = 0.05), and renal disease ( p= 0.03) (Table
3). We also evaluated comorbidities not included in the CCI
and found no association with risk of complications (Table 4).
A multivariable model was constructed to evaluate the re-
lationship of comorbid conditions and complications while
controlling for other characteristics (Table 5). In the first
model, all comorbid conditions were incorporated, including
those conditions not found in the CCI. Cerebrovascular disease
[odds ratio 3.01 (95% confidence interval [CI] 1.10, 8.26)
p= 0.03] and COPD [3.12 (1.24, 7.89) p= 0.02] independently
predicted perioperative complications after RAPN. In a second
multivariable model that excluded comorbidities not found in
CCI, similar results were yielded,with cerebrovascular disease
[2.93 (1.04, 7.56) p= 0.04] and COPD [2.69 (1.04, 6.28)
p= 0.04] as the only two significant variables. No other vari-
ables reached statistical significance in either model, including
nephrometry score or estimated blood loss ( p> 0.50 for both).
The association of individual comorbidities with major
complications (Clavien grade 3 or 4; n= 30 patients) was then
investigated. COPDwas the only comorbidity within the CCI
associated with increased rates of major complications
( p = 0.04). Hyperlipidemia also predicted major complica-
tions during RAPN in univariable analysis ( p = 0.03). These
two comorbidities were incorporated into a multivariable
model while controlling for nephrometry score, age, BMI,
and operative time. Only COPD [3.19 (1.07, 9.48) p = 0.04]
retained statistical significance in multivariable analysis.
Complications for patients with COPD include the follow-
ing: urine leak (n= 2), wound infection (n= 1), urinary retention
(n= 1), fluid overload (n= 1), postoperative blood transfu-
sion (n= 1), acute respiratory failure or hypoxia requiring
reintubation (n= 2), fever (n= 1), hemorrhage (n= 1), re-
admission for flank pain (n= 1), and non-ST segment elevation
myocardial infarction (n= 1). Complications for patients with a
history of cerebrovascular disease include the following: uri-
nary retention (n= 2), hydropneumothorax (n= 1), anemia re-
quiring blood transfusion (n= 2), atrial fibrillation (n= 1), aortic
thrombus (n= 1), hypoxia requiring reintubation (n= 1), urine
leak (n= 1), fluid overload (n= 1), non-ST segment elevation
myocardial infarction (n= 1), and pulmonary embolism (n= 1).
Discussion
The management of renal masses with RAPN has become
increasingly common,21,22 and RAPN results in similar on-
cologic outcomes as open and laparoscopic PN while de-
creasing blood loss, operative time, and length of hospital
stay.4,5,23,24 Further advantages of RAPN include three-
dimensional viewing vs two dimensions in laparoscopy and
increased dexterity.25 Complications during RAPN are not
uncommon, with reported complication rates between 15%
and 33%,13,14 leading to significant morbidity. Discovering
patient- and tumor-specific factors associated with compli-
cation rates during RAPN is paramount to improving stan-
dard of care in management of renal masses. To our
Table 2. Perioperative Complications After RAPN
Clavien grade Organ system Complications (No.)
1 (10 patients) Cardiovascular Hypotension (1)
Genitourinary Urinary retention (3), acute renal insufficiency (1)
Gastrointestinal Ileus (3)
Other Fever (1), pain (1)
2 (28 patients) Cardiovascular Postoperative hemorrhage (1), NSTEMI (1), hypotension (1), DVT
(3), aortic thrombus (1), atrial fibrillation (3), hypertension crisis
(1), BT (4), MI (1), PE (2), blood loss/anemia (1)
Genitourinary Dysuria (1), acute renal failure (1), urinary retention (2), prostate
infection (1), rectus hematoma (1)
Gastrointestinal Ileus (1)
Respiratory Shortness of breath (1)
Other Dehydration (1), fever (2), wound infection (2), flank pain (1)
3a (20 patients) Cardiovascular Pseudoaneurysm (12), BT (2), AV fistula (1)
Genitourinary Urine leak (2)
Respiratory Reintubation in PACU (1), hydropneumothorax (1), pneumonia (1),
shortness of breath/hypoxia (2), pneumothorax (1)
Lymphatic Lymphocele (1)
3b (5 patients) Cardiovascular Hemorrhage (1), pseudoaneurysm (1)
Genitourinary Incisional hernia (3)
Respiratory Shortness of breath/hypoxia (1)
4 (4 patients) Cardiovascular MI (2), BT (1)
Genitourinary Chronic renal insufficiency (1)
Respiratory Acute respiratory failure (1)
Gastrointestinal Ileus (1)
Other Persistent nausea (1)
AV= arteriovenous; BT= blood transfusion; DVT = deep vein thrombosis; MI =myocardial infarction; NSTEMI = non-ST segment
elevation myocardial infarction; PACU= postanesthesia care unit; PE= pulmonary embolism.
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knowledge, this is the first report on the relationship of spe-
cific comorbidities with RAPN complications.
Within the current literature, predictors of complications
during RAPN are still debated. Some studies have found an
association of RNS with complications,10,13 while other
studies did not find a significant association.14,26 Similarly,
the association of the CCI with RAPN complications and
hospital readmission rates is still debated.14,27 Interestingly,
one large multicenter study on RAPN found no association
between age-adjusted CCI and perioperative complications in
multivariable analysis.13 Given the etiologic heterogeneity of
conditions within the CCI,11 it seemed reasonable to propose
that only specific comorbidities within the CCI predict peri-
operative complications. Indeed, only cerebrovascular disease
and COPD were associated with adverse perioperative out-
comes, while all other comorbid conditions in the CCI were
not significantly associated with surgical complications.
The relationship of cardiovascular disease with adverse
oncologic outcomes after surgery for renal masses has recently
been demonstrated.28 An independent relationship was ob-
served between overall survival for T1aN0M0 RCC and spe-
cific comorbidities, including congestive heart failure, chronic
kidney disease, PVD, COPD, diabetes, and cerebrovascular
disease.28 The relationship between these comorbidities and
perioperative complications was not investigated, however.
The data herein build on the current literature and suggest that
patientswith cerebrovascular disease andCOPDare at a higher
risk for complications after or during RAPN.
The association of CCI with perioperative complications
has been studied in other surgical procedures. In patients
undergoing surgery for spinal cord injuries, a higher CCI is
associated with increased complication rates.29 The CCI is a
strong predictor of surgical complications in patients with
intracranial meningiomas.30 Interestingly, age-adjusted CCI







AIDS No 641 574 (89.5) 67 (10.5) —
Yes 0 — —
CVA or TIA No 611 553 (90.5) 58 (9.5) <0.001
Yes 30 21 (70.0) 9 (30.0)
COPD No 599 542 (90.5) 57 (9.5) 0.003
Yes 42 32 (76.2) 10 (23.8)
Chronic heart failure No 628 562 (89.5) 66 (10.5) 1.00
Yes 13 12 (92.3) 1 (7.7)
Connective tissue disease No 631 565 (89.6) 66 (10.4) 1.00
Yes 9 8 (88.9) 1 (11.1)
Dementia No 639 572 (89.5) 67 (10.5) 1.00
Yes 2 2 (100.0) 0 (0.0)
DM No 509 462 (90.8) 47 (9.2) 0.05
Yes 132 112 (84.8) 20 (15.2)
DM with complications No 631 566 (89.7) 65 (10.3) 0.28
Yes 10 8 (80.0) 2 (20.0)
Hemiplegia No 640 573 (89.5) 67 (10.5) 1.00
Yes 1 1 (100.0) 0 (0.0)
Leukemia No 637 572 (89.8) 65 (10.2) 0.06
Yes 4 2 (50.0) 2 (50.0)
Lymphoma No 636 569 (89.5) 67 (10.5) 1.00
Yes 5 5 (100.0) 0 (0.0)
Metastatic tumor No 637 570 (89.5) 67 (10.5) 1.00
Yes 4 4 (100.0) 0 (0.0)
Mild liver disease No 629 562 (89.3) 67 (10.7) 0.63
Yes 12 12 (100.0) 0 (0.0)
Moderate to severe liver
disease
No 638 572 (89.7) 66 (10.3) 0.28
Yes 3 2 (66.7) 1 (33.3)
Renal disease No 597 539 (90.3) 58 (9.7) 0.03
Yes 44 35 (79.5) 9 (20.5)
MI No 611 551 (90.2) 60 (9.8) 0.02
Yes 30 23 (76.7) 7 (23.3)
Peptic ulcer disease No 622 555 (89.2) 67 (10.8) 0.25
Yes 19 19 (100.0) 0 (0.0)
PVD No 627 564 (90.0) 63 (10.0) 0.05
Yes 14 10 (71.4) 4 (28.6)
Solid tumor (within last 5
years)
No 564 503 (89.2) 61 (10.8) 0.42
Yes 77 71 (92.2) 6 (7.8)
Bold= p < 0.05 and therefore considered significant.
AIDS = acquired immune deficiency syndrome; COPD= chronic obstructive pulmonary disease; CVA = cerebrovascular accident;
DM = diabetes mellitus; PVD= peripheral vascular disease; TIA= transient ischemic attack.
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is not a predictor of perioperative complications in patients
with advanced epithelial ovarian cancer.31 It is important to
note that while the utility of CCI was investigated in these
studies, some suggest that procedure-specific modifica-
tions may provide more predictive power than the current
index alone.29 As such, recent studies have investigated
the relationship of individual CCI comorbidities with
surgical outcomes, yielding mixed results regarding the
relative predictive power of individual conditions vs CCI
index.32–34







AAA No 618 553 (89.4) 65 (10.5) 1.00
Yes 23 21 (91.3) 2 (8.7)
Arrhythmia No 603 542 (89.9) 61 (10.1) 0.27
Yes 38 32 (84.2) 6 (15.8)
Asthma No 581 519 (89.3) 62 (10.7) 0.57
Yes 60 55 (91.7) 5 (8.3)
Benign prostatic
hyperplasia
No 614 548 (89.3) 66 (10.7) 0.35
Yes 27 26 (96.3) 1 (3.7)
CAD No 587 528 (89.9) 59 (10.1) 0.27
Yes 54 46 (85.2) 8 (14.8)
History of DVT No 609 548 (90.0) 61 (10.0) 0.12
Yes 32 26 (81.3) 6 (18.8)
History of stones No 529 471 (89.0) 58 (11.0) 0.40
Yes 112 103 (92.0) 9 (8.0)
Hyperlipidemia No 417 378 (90.6) 39 (9.4) 0.21
Yes 224 196 (87.5) 28 (12.5)
Hypertension No 243 223 (91.8) 20 (8.2) 0.15
Yes 398 351 (88.2) 47 (11.8)
Spinal cord injury No 641 574 (89.5) 67 (10.5) —
Yes 0 — —
AAA= abdominal aortic aneurism; CAD = coronary artery disease.
Table 5. Multivariable Analysis of Tumor- and Patient-Specific Characteristics
with Perioperative RAPN Complications
Characteristics
All comorbidities Charlson comorbidities only
Odds ratio [95% CI] p Odds ratio [95% CI] p
BMI 1.03 [0.99, 1.08] 0.16 1.03 [0.98, 1.07] 0.24
Age 1.01 [0.98, 1.05] 0.34 1.01 [0.98, 1.04] 0.35
Gender 0.95 [0.50, 1.81] 0.89 0.91 [0.48, 1.68] 0.77
Off-clamp 0.46 [0.19, 1.09] 0.08 0.50 [0.22, 1.15] 0.10
Pelvicaliceal repair 1.17 [0.56, 2.44] 0.68 1.12 [0.54, 2.34] 0.77
Operation time 1.01 [1.00, 1.01] 0.054 1.01 [1.00, 1.01] 0.07
Estimated blood loss 1.00 [1.00, 1.00] 0.99 1.00 [1.00, 1.00] 0.93
Nephrometry score 1.05 [0.87, 1.26] 0.61 1.06 [0.88, 1.27] 0.55
No comorbidity 0.38 [0.11, 1.37] 0.14 1.04 [0.14, 1.66] 0.93
AAA 0.41 [0.07, 2.33] 0.31 — —
Arrhythmia 1.45 [0.43, 4.94] 0.55 — —
CAD 0.83 [0.26, 2.63] 0.75 — —
CVA or TIA 3.01 [1.10, 8.26] 0.03 2.93 [1.04, 7.56] 0.04
COPD 3.12 [1.24, 7.89] 0.02 2.69 [1.04, 6.28] 0.04
DM 1.27 [0.64, 2.49] 0.49 1.31 [0.64, 2.39] 0.49
DVT history 2.05 [0.65, 6.50] 0.22 — —
Stones 0.83 [0.37, 1.89] 0.66 — —
Hyperlipidemia 0.70 [0.35, 1.38] 0.30 — —
Hypertension 0.73 [0.36, 1.48] 0.38 — —
Renal disease 1.76 [0.67, 4.65] 0.25 1.77 [0.66, 4.26] 0.25
MI 2.36 [0.68, 8.25] 0.18 1.94 [0.66, 5.28] 0.22
PVD 1.89 [0.44, 8.08] 0.39 1.51 [0.37, 5.97] 0.57
Solid tumor 0.43 [0.15, 1.26] 0.12 0.54 [0.19, 1.43] 0.26
Bold= p < 0.05 and therefore considered significant.
CI = confidence interval.
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All-encompassing indices such as the RNS and CCI are
advantageous in that they compress multiple measures into a
single variable; a significant disadvantage is that these
scoring systems are often developed in one disease type or
operation and may not translate well to other anatomic
systems or procedures. Due to differences in type of pro-
cedure or disease pathogenesis, different comorbidities may
differentially affect perioperative or surgical outcomes.
Considering how diverse the conditions are within the CCI,
it is not surprising that previous studies found that the CCI as
an entire measure was not significantly associated with
complication rates after RAPN.13,14 The broad applicability
of indices like RNS and CCI cannot be debated, but the data
herein suggest that close examination of each patient’s
previous medical history and the relationship to the current
illness is warranted.
Management options in the AUA guidelines for small renal
masses include active surveillance,3 and election for sur-
veillance includes both performance status and patient
preference at our institution. Patients with COPD or cere-
brovascular disease may benefit from improved preoperative
counseling regarding their risk of surgery vs other alternative
management options.
Limitations of this study include the retrospective nature of
analysis and low prevalence of some types of comorbidities.
Future prospective multi-institutional studies are required for
validation of the significance of these comorbidities. We
were unable to evaluate other measures of patient function
such as Eastern Cooperative Oncology Group performance
status or Karnofsky performance status, as collection of these
measures in this patient population was not standard for our
institution until recently. Furthermore, it is unclear whether
our results translate to other methods for nephron-sparing
surgery for renal masses, or to patients with RCC in general.
Studies are needed on a series of laparoscopic or open PN
patients to evaluate the relationship of specific CCI co-
morbidities with complication rates.
Conclusions
Cerebrovascular disease and COPD are predictors of
perioperative complications in patients undergoing RAPN,
and COPD specifically predicts major complications. Pre-
operative identification of these patients may afford im-
proved counseling and risk stratification.
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Abbreviations Used
AAA ¼ abdominal aortic aneurysm
AUA ¼ American Urological Association
BMI ¼ body mass index
CAD ¼ coronary artery disease
CCI ¼ Charlson Comorbidity Index
COPD ¼ chronic obstructive pulmonary disease
CT ¼ computed tomography
CVA ¼ cerebrovascular accident
DVT ¼ deep vein thrombosis
MRI ¼ magnetic resonance imaging
PN ¼ partial nephrectomy
PVD ¼ peripheral vascular disease
RAPN ¼ robot-assisted partial nephrectomy
RCC ¼ renal-cell carcinoma
RNS ¼ RENAL nephrometry score
TIA ¼ transient ischemic attack
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